Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study

Trial Profile

Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Sintilimab (Primary)
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ORIENT-1
  • Sponsors Innovent Biologics
  • Most Recent Events

    • 05 Jun 2018 Results (data cut off: 8 feb, 2018; n=96) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2018 Results from this trial (n=96) will be presented at the American Society Of Clinical Oncology Annual Meeitng (June 2018).
    • 16 May 2018 Status changed from not yet recruiting to recruiting, according to an Innovent Biologics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top